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Willingness of dialysis patients to participate in a randomized
controlled trial of daily dialysis.
Background. The National Institutes of Health (NIH) has
proposed conducting randomized controlled trials comparing
short, daily, in-center hemodialysis with conventional hemodial-
ysis. However, there is concern that difficulties recruiting pa-
tients may prevent the successful completion of such trials if
patients believe the inconveniences of daily dialysis outweigh
any potential health benefits.
Methods. To gauge willingness to participate in a daily dialysis
trial, we described a hypothetical, randomized controlled trial
comparing conventional to daily hemodialysis to 209 chronic
hemodialysis patients, and assessed their motivations for and
concerns about participating.
Results. We found that 85 patients (41%) of 209 patients who
agreed to be interviewed expressed some willingness to partic-
ipate in the hypothetical trial. Patients who expressed greater
willingness to participate were younger (OR for participating =
0.96 per year, 95% CI = 0.94 to 0.98, P = 0.001), less likely to
smoke (OR = 0.38, 95% CI = 0.17 to 0.84, P = 0.017), more
likely to have been hospitalized during the last 12 months (OR=
2.8, 95% CI = 1.5 to 5.5, P = 0.002), less likely to have reactive
airway disease (OR = 0.21, 95% CI = 0.06 to 0.69, P = 0.01)
or coronary artery disease (OR = 0.20, 95% CI = 0.08 to 0.53,
P = 0.001), and less likely to be on the waiting list for a kidney
transplant (OR = 0.23, 95% CI = 0.10 to 0.50, P < 0.0001).
Conclusion. The study suggests that less than half of eligible
patients would be willing to participate in the randomized con-
trolled trial. Differing willingness to participate across patient
subgroups suggests that certain subgroups (i.e., older patients
and those with coronary artery disease) will need to be targeted
to ensure that results are generalizable to most hemodialysis
patients.
Long-term hemodialysis has been recognized as a life-
saving intervention since the 1970s. A three-times-per-
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week regimen has been the standard of care for most
hemodialysis patients. However, this regimen has been
based primarily on practical considerations of transporta-
tion and scheduling a rapidly growing number of end-
stage renal disease (ESRD) patients requiring chronic
dialysis rather than demonstrated superiority to other
regimens [1, 2]. Recently, case series conducted in the
United States, Canada, and Europe have highlighted
the putative advantages of short, daily hemodialysis (in-
center treatments six times each week) [abstracts; Ting
et al, Perit Dial Int 18:S78A, 1998; Ting et al, J Am Soc
Nephrol 9:228A, 1998; Ting et al, J Am Soc Nephrol
9:228A, 1998; Buoncristiani et al, J Am Soc Nephrol 8:
216A, 1997; Buoncristiani, J Am Soc Nephrol 8:216A,
1997] [3–8]. Despite these reported advantages of daily
dialysis, the absence of randomized controlled trials com-
paring conventional to daily dialysis prevents robust con-
clusions regarding which is to be preferred. To improve
decision-making for the approximately 300,000 patients
requiring long-term dialysis in the United States [9], the
National Institutes of Health (NIH) has proposed fund-
ing for randomized controlled trials of daily hemodialysis
in which dialysis patients would be randomly assigned to
receive daily hemodialysis (six times a week) or conven-
tional hemodialysis (three times a week) [10, 11].
A major barrier to the successful conduct of random-
ized controlled trials is the difficulty recruiting eligible
patients [12–16]. Recruitment may be particularly dif-
ficult for the proposed randomized controlled trials of
daily hemodialysis because patients may view the incon-
venience of daily dialysis to outweigh any potential health
benefits of daily dialysis. Therefore the proposed trials
may experience underenrollment—the enrollment of too
few subjects to obtain adequate statistical power to reli-
ably detect an effect—and selective enrollment—the dis-
proportionate enrollment of certain patient subgroups
(e.g., those with relatively few comorbid illnesses). These
phenomena would threaten the precision and generaliz-
ability of the results, respectively [13].
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One method to help overcome these problems is to
prospectively assess potential research participants’ pref-
erences for trial enrollment. Prospective preference as-
sessment may enhance the subsequent trial’s scientific
value in several ways [13]. First, identifying patients for
whom research participation is consistent with their in-
terests and values may enhance the efficiency of partici-
pant accrual by guiding recruitment efforts toward those
most likely to agree to enroll. Second, prospectively as-
sessing willingness to participate among members of the
target population may provide insight into the general-
izability of the results. Third, identifying individuals with
sincere interests in participating may help investigators
enroll patients who are more likely to adhere to study
protocols [17], reducing the potential for bias due to post-
randomization losses [18].
To help guide the conduct of proposed randomized
controlled trials of daily hemodialysis, we prospectively
assessed dialysis patients’ stated willingness to partici-
pate in a hypothetical trial that mimicked those likely
to be initiated through support from the NIH [19]. We
had three primary goals. Our first goal was to gauge the
likelihood for successful enrollment in actual random-
ized controlled trials once initiated. Second, we aimed
to determine ESRD patients’ motivations for and con-
cerns about participating in such a trial so as to guide
the design and conduct of future randomized controlled
trials. Finally, we sought to evaluate differences in demo-
graphic and disease-related characteristics among those
who are and are not likely to enroll in actual trials so
as to anticipate the generalizability of the results from
future randomized controlled trials. Our secondary aim
was to determine the effect of formalized teaching about
the risks and benefits of daily dialysis on patients’ stated
willingness to participate in the proposed trial.
METHODS
Patients
Between July 2002 and December 2002, we enrolled
patients receiving chronic hemodialysis at the three dial-
ysis units affiliated with the University of Pennsylvania
Medical Center. Two of the dialysis units were urban and
the third one was a suburban unit. A total of 331 pa-
tients were receiving dialysis during this period. We aimed
to include all patients except those who were unable to
speak English or understand the consent form (e.g., due
to dementia). Sixty-one patients (18%) refused to par-
ticipate, 18 (5%) were unavailable for interview, and 18
(5%) met the foregoing exclusion criteria. The remain-
ing 234 patients gave written, informed consent and were
interviewed while on dialysis. None of the patients were
offered a financial incentive for participating in our sur-
vey study. This study was approved by the University of
Pennsylvania Institutional Review Board (Fig. 1).
Study design
One of the four physician investigators not involved in
the care of the dialysis patients at the time of the study in-
terviewed each patient individually for approximately 15
minutes during one of their dialysis sessions. During the
first part of the interview, the investigator read a scripted
description of a 3-year, hypothetical, randomized con-
trolled trial comparing conventional (three times weekly)
hemodialysis with daily (2-hour treatments, six times
weekly) dialysis (see Appendix 1). This hypothetical
trial reflected the design features the investigators antic-
ipate will be employed in an upcoming, actual random-
ized controlled trial of conventional versus daily dialysis.
These design features were based on a NIH-sponsored
conference on daily dialysis [19]. The investigator also re-
viewed the potential benefits of daily dialysis using a pre-
viously piloted script. Several small case series indicate
that daily dialysis may improve several surrogate mark-
ers of health, such as blood pressure control, hematocrit,
and serum albumin and prealbumin, as well as the true
clinical end points of reduced symptoms such as cramp-
ing and headaches, and an overall improvement in qual-
ity of life [3, 6, 7, 20, 21]. There is hope, albeit limited
evidence, that more frequent dialysis regimens might re-
duce hospitalizations, reduce use of erythropoietin and
blood pressure medications, and extend life expectancy
[8, 22]. The investigator also reviewed the potential risks
of daily dialysis using a previously piloted script. These in-
clude the uncertain risks of vascular access failure associ-
ated with more frequent use. The investigator then asked
the patient four previously scripted questions [13] to as-
sess the patient’s understanding of the described trial.
These four questions assessed the patient’s understand-
ing of randomization, differences between the two arms
of the trial and the duration of the trial (see Appendix
1). Any areas of misunderstanding were explained, and
the patient was then requestioned. Twenty-five patients
(8%) were excluded because they failed to demon-
strate adequate understanding. Most of these excluded
patients had a poor understanding of the concept of
randomization.
The remaining 209 patients (Fig. 1) were asked open-
ended questions about their motivations for, and con-
cerns about participating in the hypothetical trial. The
patients were encouraged to state as many motivating
and concerning factors that were important to them.
Their responses were transcribed and subsequently cate-
gorized. Next, the investigator asked patients to indicate
their willingness to participate in the described trial (this
represented the baseline willingness to participate) us-
ing a 6-point scale from “definitely not willing” to “defi-
nitely willing.” Patients also completed a two-page form
assessing demographic characteristics, disease-related
characteristics, and comorbidities. Disease-related char-
acteristics, including treatment variables, medications
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331 Prevalent dialysis patients
18 (5%) Excluded due to dementia/
aphasia
25 (8%) Failed knowledge quiz
61 (18%) Refused to take survey
18 (5%) Unavailable due to transfer/
hospitalization/death
8 (4%) Refused to take survey
19 (9%) Unavailable due to transfer/
hospitalization/death
N = 209: Assess motivations, concerns, baseline
willingness to participate
N = 177: 2nd assessment of willingness to
participate
5 (2%) Transplanted
Fig. 1. Patients participating in the first and second part of the survey. For the baseline assessment of their willingess to participate, 122 (37%) of
the 331 dialysis patients in our cohort study could not be surveyed. For the second assessment of their willingness to participate, 32 (15%) of the
209 patients could not be surveyed. At least three attempts were made over the 6 months of the study to capture all patients in the cohort.
currently being taken, and whether or not the patient
had been listed for renal transplantation, were con-
firmed by abstracting data from the patients’ medical
records.
Approximately 1 month after their initial interview, pa-
tients were provided a one-on-one verbal teaching ses-
sion that was scripted and led by one of the investigators
during one of their dialysis treatments. This session again
presented information in detail regarding the potential
health benefits, risks, and inconveniences associated with
the novel, daily dialysis regimen (see Appendix 2). Once
patients had completed the formal teaching, investiga-
tors reassessed their willingness to participate using the
same 6-point scale. Of the 209 patients who had partic-
ipated in the first part of the survey, 32 (15%) were un-
able or unwilling to participate in this second assessment
of their willingness to participate. The remaining 177
patients (85%) participated in the second interview.
(Fig. 1)
Statistical analysis
We used Student t tests to compare those willing to
participate and those unwilling to participate with regard
to normally distributed variables, and chi-squared tests
for comparisons on categorical variables. We constructed
both an ordinal logistic regression model (using stated
willingness to participate as an ordinal variable) and
a logistic regression model (using stated willingness to
participate as a dichotomous variable) to evaluate the in-
fluence of the various patient characteristics (such as co-
morbid illnesses and demographic factors) on willingness
to participate in the trial. We dichotomized willingness to
participate a priori, by considering all patients who gave
a positive response on the 6-point scale (“might, “prob-
ably,” or “definitely” willing to participate) as willing to
participate. Because the direction of effect of the coeffi-
cients for the attributes were similar in the dichotomous
and the ordinal logistic regression models, we present
only the results of the dichotomous model because this
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Table 1. Characteristics of survey patients (number in parenthesis is percentage unless otherwise stated)
All patients Not willing to participate Willing to participate
(N = 209) (N = 124) (N = 85)
Age years (± SD) 56 ± 15 58 ± 14 52 ± 15a
Female 106 (51%) 66 (52%) 40 (47%)
Race
Non-Hispanic African Americans 173 (83%) 103 (83%) 70 (82%)
Non-Hispanic white 25 (12%) 16 (13%) 9 (11%)
Others 11 (5%) 5 (4%) 6 (7%)
Years of education (± SD) 12.7 (± 2.5) 12.6 (±2.5) 12.7 (±2.5)
Mean household incomeb $15,001–30,000 $15,001–30,000 $15,001–30,000
Employed 30 (14%) 15 (12%) 15 (18%)
Mode of transportation
Personal 95 (45%) 53 (43%) 42 (49%)
Public 27 (13%) 17 (13%) 10 (12%)
Institutional 87 (42%) 54 (44%) 33 (39%)
Current smoker 50 (24%) 35 (28%) 14 (17%)
Length of time on dialysis years 4.0 ± 4 4.3 ± 4.2 3.6 ± 3.7
Number of hospitalizations last year 1.5 ± 2.4 1.1 ± 1.8 2.0 ± 3.0a
Transplant waiting-list status
Evaluated for kidney transplantation 111 (53%) 71 (57%) 40 (47%)
On list for kidney transplantation 62 (30%) 45 (36%) 17 (20%)a
Stated quality of personal health
Excellent 6 (3%) 5 (4%) 1 (1%)
Very good 30 (14%) 18 (15%) 12 (14%)
Good 62 (30%) 34 (27%) 28 (33%)
Fair 84 (40%) 52 (42%) 32 (38%)
Poor 27 (13%) 15 (12%) 12 (14%)
Vascular access type
Arteriovenous fistula 72 (35%) 45 (36%) 27 (32%)
Arteriovenous grafts 102 (50%) 59 (49%) 43 (51%)
Catheter 32 (16%) 18 (15%) 14 (17%)
Average Kt/V for last 3 months 1.47 (0.2) 1.47 (± 0.2) 1.46 (± 0.2)
Treatment time hours per week 11.3 (1.7) 11.1 (± 1.6) 11.5 (± 1.7)
aP < 0.05; bFifteen patients did not give this information.
better reflects the decision that patients must ultimately
make. We included in the multivariable model all vari-
ables reaching P < 0.20 in univariable analyses. We used
McNemar’s test to compare willingness to participate at
baseline and after formal teaching. P values <0.05 were
considered statistically significant.
With 209 patients enrolled, and at an alpha level of 0.05,
we had at least 80% power to detect differences of 20%
in the proportions of patients who were willing to par-
ticipate when patient subgroups were defined such that
from 30% to 70% of patients had a particular comorbid
condition.
RESULTS
The characteristics of the 209 patients who completed
the first interview are described in Table 1. Overall, the
percentages of patients who said they “definitely would
not,” “probably would not,” “maybe would not,” “may be
would,” “probably would,” and “definitely would” partic-
ipate were 29%, 21%, 9%, 17%, 17%, and 7%, respec-
tively. Thus, 85 of the 209 survey patients (41%) were
considered willing to participate in a randomized con-
trolled trial of short daily hemodialysis (Fig. 2).
0
5
10
15
20
25
30
35
40
45
Pe
rc
en
ta
ge
 o
f p
at
ie
nt
s
De
fin
ite
ly n
ot
Ma
yb
e w
ou
ld
Pro
ba
bly
 wo
uld
De
fin
ite
ly w
ou
ld
Pro
ba
bly
 no
t
Ma
yb
e n
ot
Baseline
2nd assessment
Willingess to participate
Fig. 2. Response to question: How willing would you be to partici-
pate in this study of six versus three times a week dialysis? At baseline
among 209 patients, 85 (41%) stated a positive willingness to participate
whereas 124 (59%) were not willing to participate. After teaching about
the possible risks and benefits of daily dialysis, among 177 patients, 62
(35%) stated a positive willingness to participate whereas 115 (65%)
were not willing to participate.
Influence of demographic and disease-related
characteristics on willingness to participate
Univariable analyses revealed that, compared with pa-
tients who were unwilling to participate, those who were
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Table 2. Variables associated with willingness to participate: A univariate and multivariate analysisa
Variable Unadjusted OR (95% CI) Unadjusted P value Adjusted OR (95% CI) Adjusted P value
Age per year 0.97 (0.95–0.99) 0.004 0.96 (0.94–0.98) 0.001
Hospitalization last year 2.37 (1.3–4.2) 0.003 2.8 (1.5–5.5) 0.002
Current smoker 0.54 (0.28–1.08) 0.081 0.38 (0.17–0.84) 0.017
Dialysis treatment time, per hour 1.15 (0.97–1.36) 0.113 —
On list for kidney transplant 0.44 (0.23–0.84) 0.012 0.23 (0.10–0.50) <0.0001
Evaluated for a kidney transplant 0.66 (0.38–1.15) 0.147 —
History of reactive airway disease 0.32 (0.12–0.90) 0.031 0.21 (0.06–0.69) 0.011
History of coronary artery disease 0.22 (0.09–0.52) 0.001 0.20 (0.08–0.53) 0.001
History of arrhythmia 0.53 (0.30–0.96) 0.035 —
History of coronary artery bypass grafting 0.25 (0.05–1.15) 0.074 —
History of coronary angioplasty 0.25 (0.7–0.88) 0.030 —
aVariables that were not significantly associated with willingness to participate by univariate anlaysis include gender, race, years of education, mean household income,
employment status, mode of transportation, dialysis unit, location of dialysis unit (suburban versus urban location), interviewer, length of time on dialysis in years,
stated quality of personal health, type of vascular access, and disease-related factors such as albumin, calcium-phosphorus product, Kt/V, number of medications for
hypertension, and number of phosphate binders.
willing to participate were younger, nonsmokers, and
more likely to have been hospitalized in the preceding
12 months, and not on the waiting list for a renal trans-
plant. Patients who were willing to participate were also
less likely to have a history of reactive airway disease
(asthma or emphysema), arrhythmias, coronary artery
disease, or a coronary angioplasty (Table 2). Several of
these differences remained significant after adjustment
for confounding in multivariable analysis (Table 2). In
the multivariable model, we found that patients who were
willing to participate in the randomized controlled trial
were younger, nonsmokers, and more likely to be hospi-
talized in the preceding 12 months. They were also less
likely to be on the waiting list for a kidney transplant and
less likely to have a history of reactive airway disease or
coronary artery disease.
Several motivations and concerns differed among pa-
tients who were and were not willing to participate in the
hypothetical randomized controlled trial. For example,
patients who were willing to participate cited personal
health benefit as a motivating factor nearly twice as com-
monly as those unwilling to participate (Table 3). Shorter
treatment time, need for fewer medications, and altruism
were also cited more often by those willing to participate.
In contrast, patients unwilling to participate were twice
as likely to cite the inconvenience of coming 6 days as
a concern as those willing to participate. Many patients
stated concerns such as “[daily dialysis] would interfere
with work,” “when would I take care of my other medical
appointments [on daily dialysis]?,” “it is stressful to come
after a full day of work; a lot of my strength is gone after
[a] dialysis [treatment].”
Some patients stated concerns about social isolation
with daily dialysis. “I could never do anything with my
wife,” “I spend weekends visiting my grandchildren,” “I
will not be able to spend time with my family.” Others
voiced concerns about their vascular access with daily
dialysis. “My access infiltrates when I get stuck on 2 days
back to back,” “sometimes it takes 48 hours for the needle
Table 3. Responses to question regarding randomized controlled
trial of daily dialysis: What things would make participating appeal to
you number (%)?
All Not willing to Willing to
patients participate participate
(N = 209) (N = 124) (N = 85)
Personal health 77 (37%) 33 (27%) 44 (52%)a
benefit
Other benefits: shorter 89 (43%) 44 (36%) 45 (53%)a
treatment, etc.
Fewer medications 25 (12%) 10 (8%) 15 (18%)b
Altruism 11 (5%) 1 (1%) 10 (12%)a
Contribute to knowledge 5 (2%) 2 (2%) 3 (4%)
Better access to 2 (1%) 0 (0%) 2 (2%)
care
aP < 0.0001, comparing those not willing to participate versus those willing
to participate; bP < 0.05, comparing those not willing to participate versus those
willing to participate.
site to heal,” “I have poor veins,” “[daily dialysis] would
blow my graft.” However, there were no differences be-
tween patients who would or would not participate in
the randomized controlled trial in the proportions of pa-
tients citing social isolation or fear of side effects (i.e.,
loss/damage to vascular access) as concerns (Table 4).
Older patients, defined as age older than 56 years, had
similar motivating factors as those patients younger than
56 years old. However, older patients were more likely to
state no motivating factors than younger patients (51%
versus 31%, P < 0.01). These older patients were also
more likely to cite the inconvenience of coming 6 days
a week for dialysis than younger patients (72% versus
54%, P < 0.01).
Patients with comorbid conditions such as history of
coronary artery disease or reactive airway disease had
similar motivating factors as those patients without these
cormobidities. However, patients with these comorbidi-
ties were more likely to state no motivating factors than
patients without these comorbidities (56% versus 35%,
P < 0.01). These patients with comorbities were also
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Table 4. Responses to question regarding randomized controlled
trial of daily dialysis: What things concern you about participating
number (%)?
All Not willing to Willing to
patients participate participate
(N = 209) (N = 124) (N = 85)
Inconvenience of coming 132 (63%) 102 (83%) 30 (35%)a
6 days
Other concerns: Social 76 (36%) 50 (40%) 26 (31%)
isolation, etc.
Fear of side effects 64 (31%) 33 (27%) 31 (36%)
Skeptical of research 1 (1%) 0 (0%) 1 (1%)
Effect on other illness 3 (1%) 1 (1%) 2 (2%)
aP < 0.0001, comparing those not willing to participate versus those willing to
participate.
more likely to cite the inconvenience of coming 6 days
a week for dialysis than patients without these comor-
bidities (78% versus 57%, P < 0.01).
Influence of teaching on willingness to participate
Of the original 209 patients, 177 (85%) agreed to and
were available for the second interview. The remaining
32 were lost due to death (6), transfer to another dialysis
unit (7), hospitalization (6), transplantation (5), or refusal
to be interviewed again (8). Overall, the percentages of
patients who said they “definitely would not,” “probably
would not,” “maybe would not,” “maybe would,” “prob-
ably would,” and “definitely would” participate were now
41%, 19%, 5%, 14%, 10%, and 11%, respectively. Thus,
35% of the 177 surveyed patients said they were willing
to participate in an randomized controlled trial of daily
dialysis after extensive teaching about the regimen’s po-
tential benefits (Fig. 2). Within patients, there was no ap-
preciable change in willingness to participate between the
preteaching and postteaching assessments (McNemar’s
chi-square = 2.19, P = 0.14). However, in the postteach-
ing assessment, there was a polarizing effect toward more
responses being “definitely yes” or “definitely no”
(Fig. 2). Those who could not be surveyed for the
postteaching assessment did not differ from those who
completed both assessments in their distributions of age,
gender, race, education, income or baseline willingness
to participate (data not shown). Although our study was
not specifically powered to detect such differences, these
null findings suggest that the analyses of the influence of
teaching on willingness to participate are not biased by a
selected group of individuals not being available for the
second assessment.
DISCUSSION
We found that 41% of 209 patients who agreed to be
interviewed at our inner city and suburban dialysis cen-
ters indicated a willingness to participate in a hypothetical
trial comparing conventional with daily dialysis (Fig. 2).
To the extent that this stated willingness to participate
predicts the actual enrollment decisions patients would
make [23], this result suggests that the majority of ESRD
patients may not agree to enroll in upcoming randomized
controlled trials.
Most of the patients in our sample who would partici-
pate in the randomized controlled trial cited the potential
for personal health benefits. Potential health benefits
have been cited as common motivations among patients
considering enrollment in cancer and cardiovascular
treatment trials [24–27]. However, a recent systematic
review suggested that across all diseases, altruism is the
most commonly cited motivation for participating in ran-
domized controlled trials [16]. Altruism appears to be a
particularly common motivation among human immun-
odeficiency virus (HIV)-infected patients [28] and those
at high risk for HIV infection [29]. Thus, our results sug-
gest that patients with ESRD may be similar in their en-
rollment preferences to patients with other noninfectious
chronic diseases.
In order to gain insight into the factors governing
ESRD patients’ decisions, we compared the motivations
and concerns among patients who were and were not will-
ing to participate in the trial. We found that patients who
were willing to participate were almost twice as likely to
point to primary personal health benefits as a motivat-
ing factor in their decision to participate. These patients
were also more likely to cite other personal benefits such
as shorter treatment time and the need for fewer medi-
cations (Table 3).
On the other hand, we found that a substantial propor-
tion of ESRD patients would not participate because of
the inconvenience of coming to dialysis 6 days a week.
Inconvenience of coming to the unit was cited twice as
commonly among those who said they would not partic-
ipate as among those who said they would participate,
despite there being no difference between these groups
in their mode of transportation or length of time spent
in transit for each session. Inconveniences of daily dial-
ysis was cited more often by older patients and patients
with comorbid conditions such as coronary artery dis-
ease or reactive airway disease than by younger patients
and patients without these comorbidities. Concerns about
the inconveniences of daily dialysis were also noted by
patients undergoing daily dialysis in small pilot studies
[8].
Nearly one third of patients were concerned about the
possibility of side effects from daily dialysis, particularly
the possibility that more frequent treatments would more
quickly damage their access sites. We suggest that pilot
studies of daily dialysis focus on the effects on the vascu-
lar access site; if such studies do not show significantly in-
creased risks to access patency, relaying this information
to patients may help augment participation in upcoming
randomized controlled trials.
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To estimate the generalizability of results of upcoming
randomized controlled trials of daily dialysis, we inves-
tigated whether certain patient subgroups were more or
less willing to become part of these trials’ samples. First,
we found that patients on the waiting list for kidney trans-
plantation were less likely to participate. This may be at-
tributable to these patients’ reluctance to alter their care
in the hopes of soon receiving a treatment with better life
expectancy and quality of life.
Second, we found that in general, patients with fewer
comorbidities were more willing to participate. Patients
willing to participate were younger, more likely not to
smoke, and less likely to have a history of reactive air-
way disease, or coronary artery disease. We might have
expected the sicker patients to be more willing to partici-
pate in the trial in the hopes of receiving an intervention
that would be more effective in reducing their mortal-
ity. Such considerations may explain why acutely ill pa-
tients who were hospitalized in the preceding 12 months
were more willing to participate. However, the present
observations suggest patients with more chronic comor-
bid illnesses may perceive that they are more burdened by
their disease, and thus less able to accommodate changes
to their treatment regimen.
Regardless of the basis for differences in willingness
to participate between more and less ill patients, the ex-
istence of these differences suggests that several patient
sub-groups, such as those who are older, who smoke, or
who have cardiac disease, may need to be specifically tar-
geted to ensure that upcoming trials of daily dialysis are
generalizable to most ESRD patients. Further efforts to
understand the factors that would motivate or deter par-
ticipation among these subgroups could aid in augment-
ing recruitment.
Our study has at least three limitations. First, 18% of re-
cruited ESRD patients refused to be surveyed. To protect
the confidentiality of those unwilling to be interviewed,
we did not explore ways in which these patients may
have differed from the 82% who were willing to be in-
terviewed. If differences exist, and if these differences
are strongly associated with willingness to participate,
this could have biased our estimate of the proportion
of patients willing to participate in a future trial. As-
suming that the 18% who refused to be surveyed would
also refuse to participate in a randomized controlled trial
of daily dialysis, only 32% of eligible patients would
have been potentially willing to participate in such a
trial.
A second limitation of this study is that our patients
were predominantly African American. Among previous
studies evaluating patients’ preferences for trial enroll-
ment, some have found that African American patients
are less willing to participate than other patients [23].
whereas other studies have found no association between
race and willingness to participate [25]. Lower willingness
to participate among some groups of African American
patients has been attributed to distrust of the medical
profession. Among our sample, however, distrust of re-
searchers or of research in general was rarely cited as
a concern. Thus, we see no reason to assume that higher
rates of willingess to participate will be found among sam-
ples with different racial compositions, but we cannot rule
out this possibility.
Finally, we evaluated patients’ stated willingness to par-
ticipate in an upcoming trial so as to help guide design and
recruitment of this trial, but we cannot be sure that those
who say they would or would not participate would make
similar decisions when actually faced with this choice.
Earlier work suggests that among patients at high risk
for HIV infection stated willingness to participate is the
single best predictor of who will and will not ultimately
enroll in real trials [23]. However, stated willingness to
participate is an imperfect surrogate for enrollment, and
understanding its predictive properties among patients
with ESRD will require future investigations once actual
trials are initiated.
CONCLUSION
This study represents the first investigation of the will-
ingness of ESRD patients to participate in a trial com-
paring conventional to daily dialysis. Our findings have
many implications for the planned randomized controlled
trials of daily dialysis. First, our results suggest that less
than half of ESRD patients who are recruited will ulti-
mately participate in such an randomized controlled trial.
This suggests that many dialysis centers would have to
be involved to ensure adequate enrollment. Second, be-
cause our teaching intervention failed to improve enthu-
siasm for trial participation, investigators cannot assume
that simply informing patients of the potential benefits
of daily dialysis will improve enrollment. Rather, investi-
gators will need to develop novel approaches to address
patients’ concerns. Investigators will also need to address
patients’ concerns regarding the inconveniences of com-
ing 6 days a week for dialysis on an individual basis. Future
investigations should also assess patients’ willingness to
participate in trials of daily dialysis where the study de-
sign is modified. For example, it is not known if a run-in
period of daily dialysis would allow patients to experi-
ence some of the short-term benefits of daily dialysis and
thereby improve subsequent enrollment. Finally, in order
to ensure generalizability to most ESRD patients, inves-
tigators might explore ways to target sub-groups of pa-
tients (i.e., older patients and those with coronary artery
disease) who may be otherwise underrepresented.
ACKNOWLEDGMENTS
A.K.I. has been supported by NIH F32 DK60298-01 and NIH K23
DK60298-01 grant. This project has been supported by a University of
Israni et al: Patient’s preference for trial of daily dialysis 997
Pennsylvania Research Foundation grant to A.K.I. and J.S.B. Special
thanks to Hatem Amer, M.D., for his assistance with interviewing the
dialysis patients. Part of this research was presented at the 2002 Amer-
ican Society of Nephrology meeting in Philadelphia.
Reprint requests to Ajay K. Israni, M.D., Center for Clinical Epidemi-
ology & Biostatistics, 102 Blockley Hall, 423 Guardian Drive, Philadel-
phia, PA 19104.
E-mail: aisrani@cceb.med.upenn.edu
APPENDIX 1: DESCRIPTION OF
HYPOTHETICAL TRIAL (TO BE READ
TO EACH PATIENT)
Research Study of Six Times a Week,
In-Center Hemodialysis
Researchers at the University of Pennsylvania are planning to study
a new dialysis schedule to treat kidney failure. Patients using this new
schedule would receive their regular dialysis treatment six times each
week, with each treatment lasting for 2 hours.
Some patients have previously been tested in smaller studies of six
times a week dialysis. In these early studies, there did not appear to
be any risks to having dialysis six times each week. The more frequent
treatments did appear to have several benefits for patients. These pa-
tients had better blood pressures with the use of fewer medications,
better blood counts with use of less medicines, and better results of
other routine blood tests, including phosphate and calcium levels.
Most patients also felt better when getting six times a week dialysis
treatments. For example, these patients had less cramps and nausea.
However, we are not sure that all patients will have these benefits. It is
also possible that getting dialysis six times each week may increase the
chance that patients would need to have a procedure to repair the site
at which they are hooked up to the dialysis machine.
To further study the risks and benefits of having dialysis treatments
six times each week, researchers need 2000 patients like yourself to
participate in a larger study comparing six times a week dialysis with
three times a week dialysis. This study will last 3 years.
During the 3-year study, half of the study patients will continue their
regular three times a week dialysis, and the other half will be changed to
six times a week dialysis. Whether you receive six times a week dialysis
or continue your regular three times a week dialysis will be determined
by chance, like flipping a coin. Neither patients nor their doctors will
get to choose whether they receive dialysis three or six times each week.
Those patients assigned to receive dialysis six times a week would go to
their regular dialysis units every day of the week except Sunday, to be
treated for 2 hours each day. Patients would not be charged for any of
these treatments.
If the six times a week hemodialysis is shown to be safe and effective,
you and other people needing dialysis might be able to receive six times
a week dialysis as treatment in the future.
Questions Assessing Patients’ Understanding of the Trial
1. Can you tell me how it will be decided which patients in this study
get three times a week dialysis and which will get six times a week
dialysis?
2. If you are assigned to receive dialysis six times a week, would each
treatment last for longer, shorter, or about the same amount of
time as the treatments you currently get three times each week?
3. How long will this study last?
4. Do you have any questions about what the study?
Open-Ended Questions About Factors Influencing
Enrollment Decisions
1. In thinking about this study, what things would make participating
appeal to you?
2. In thinking about this study, what things concern you about par-
ticipating?
Question Assessing Willingness to Participate
1. How willing would you be to participate in this study of six versus
three times a week dialysis? Please answer with one of the follow-
ing six levels of willingness: “I would definitely not participate,”
“I would probably not participate,” “I might not participate,” “I
might participate,” “I probably would participate,” or “I definitely
would participate.”
1 2 3 4 5 6
Definitely Probably Might Not Might Probably Definitely
Not Not
APPENDIX 2: DESCRIPTION OF TEACHING
SESSION (TO BE READ TO EACH PATIENT)
Daily Dialysis Teaching
In 1970s regular dialysis was started to save lives of people with kid-
ney disease like yourself. Hemodialysis has generally been done three
times a week. Clearly, dialysis done this way has greatly benefited pa-
tients with kidney failure, improving their life expectancy, and quality
of life.
Recently, it has been suggested that dialysis done more than three
times a week may be even better for dialysis patients.
What is daily dialysis? It is like your regular dialysis but with shorter
treatment of only 2 hours but done 6 days a week (all days except
Sunday), rather than your usual three times a week treatments for 3 to
4 hours.
Daily dialysis has been tried in small groups of patients in the United
States, Canada, and Europe.
The more frequent treatments appear to benefit patients. We will
now describe these potential benefits:
Daily dialysis may be better for controlling your blood pressure: (1)
it may lead to better blood pressure control; (2) fewer medicines may be
needed for high blood pressure; and (3) better blood pressure control
causes less stress on the heart and less heart disease
Keep in mind that heart disease is the number one killer in dialysis
patients. Daily Dialysis may improve your red blood count: (1) it may
lead to higher red blood count; and (2) higher blood count causes less
stress on the heart, less heart disease, better energy level, and better
ability to be active and do execise
Daily dialysis may allow you to have fewer restrictions in your diet.
With daily dialysis: (1) patients can eat more of the foods they like; and
(2) patients can drink more of the things they like.
Daily dialysis may cut down on the need for medicines: (1) fewer
medicines may be needed to treat high blood pressure; (2) some might
be able to stop these high blood pressure medicines altogether; and (3)
fewer medicines may be needed to control the phosphorous level.
Daily dialysis may make you feel better: (1) less cramps on daily
dialysis; (2) less nausea on daily dialysis; and (3) patients seem to feel
their best more often on daily dialysis than with regular three times a
week dialysis.
Daily dialysis may reduce need for hospital admissions. In the long-
run, daily dialysis may reduce the need for hospital admission, reduce
the number of days needed in the hospital, and increase the chance of
living longer.
So far, daily dialysis has been safe, with no harmful side effects. Pa-
tients in Europe and Canada who have received daily dialysis have not
needed extra procedures to repair the site at which they are hooked
up to the dialysis machine. However, only a few patients have received
daily dialysis so far. It is possible that daily dialysis may increase the
chance that patients would need to have a procedure to repair the site
at which they are hooked up to the dialysis machine (your shunt, fistula,
or graft) [pointing to patient’s access site].
To further study the risks and benefits of daily dialysis, we are plan-
ning a research study of daily dialysis. This study will last 3 years and
allow 2000 patients like yourself from all over the country to participate.
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During the 3 years of the study, one half the patients will continue
their regular three times a week dialysis for the usual length of time,
and the other half will be changed to six times a week daily dialysis for 2
hours as we discussed earlier. Neither patients nor their doctors will get
to choose whether they receive dialysis three or six times each week. It
will be determined by chance, like flipping a coin.
If you decide to participate in the study of daily dialysis, you would
not be charged for these dialysis treatments. We would pay for your ride
to and from the dialysis unit
If six times a week daily dialysis is shown to be safe and effective,
you and other people needing dialysis might be able to receive six times
a week dialysis as treatment in the future.
We would allow you to participate in the study of daily dialysis only
if your doctor agrees that it is safe for you.
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